Functional Imaging Reserve in NeuroHIV (FIRN)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Regina Thompson, BS
- Phone Number: 3147478421
- Email: thompson.r@wustl.edu
Study Contact Backup
- Name: Liz Westerhaus, MA
- Phone Number: 3147471125
- Email: elizabethwesterhaus@wustl.edu
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 20 to 80 years old
- documented HIV infection for at least 1 year or confirmed HIV - status
- PLWH must be on stable cART regimen for at least 12 months with undetectable plasma HIV RNA (less than 50 copies per mL)
- at least 9 years of education
- able to provide informed consent
- if female, a negative pregnancy test and not breast feeding
- able to undergo an MRI scan
Exclusion Criteria:
- significant neurological disorders (e.g. stroke, head injury with loss of consciousness for more than 5 minutes, developmental learning disability)
- active uncontrolled Axis I psychiatric disorder according to the DSM 5
- current or history of substance use disorder (including, but not limited to amphetamines, cocaine, alcohol, opiates, and barbiturates)
- prescribed blood thinners
- allergic to lidocaine or similar anesthetic
- history of any bleeding disorder
- contraindication to MRI scanning (e.g. claustrophobia, pacemaker, etc.)
- pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Persons Living with HIV (PLWH)
Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
|
3T Prisma MRI
Blood (plasma and cellular) will be collected.
CSF will be collected
|
|
HIV- Controls
Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
|
3T Prisma MRI
Blood (plasma and cellular) will be collected.
CSF will be collected
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brain Efficiency and Recruitment - Determine the neuroimaging signatures of brain efficiency and recruitment in virologically suppressed PLWH.
Time Frame: 5 years
|
The investigators will compare the recruitment of compensatory networks between the PLWH and HIV- controls using multiple linear regression.
In exploratory analyses the investigators will compare the brain efficiency between PLWH and HIV-, using similar multiple regression models, controlling for confounders.
Among PLWH, the investigators will study the association of brain efficiency with neuropsychological performance testing using multiple regression models.
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effects of Aging - Determine the effects of aging on brain efficiency and recruitment in virologically suppressed PLWH.
Time Frame: 5 years
|
The investigators will compare the recruitment (response) between the four HIV age groups (HIV- <50 year old, HIV- ≥50 years old, HIV+ <50 years old, and HIV+ ≥50 years old) using a multiple regression (ANCOVA) model, adjusting for potential confounders (age, sex, education, past substance use, and CVD).
The pairwise comparisons of primary interest is between the HIV- <50 years old and the HIV- ≥50 years old groups.
Among the PLWH only, the investigators will compare the brain efficiency r (response) between the younger and older group using multiple regression, adjusting for potential confounders.
Secondly, a mediation analysis will examine the role of immune dysfunction (activation and exhaustion) markers as mediators of this relationship.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Beau M Ances, MD, PhD, Washington University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Investigative Techniques
- Therapeutics
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Biopsy
- Physical Phenomena
- Electromagnetic Phenomena
- Magnetic Phenomena
- Diagnostic Techniques, Neurological
- Electromagnetic Radiation
- Radiation
- Radiation, Ionizing
- Spinal Puncture
- X-Rays
Other Study ID Numbers
Other Study ID Numbers
- 201805047
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.